BReast cancer Ex vivo Anthracycline Sensitivity Test (BREAST)- Using ex vivo drug sensitivity tests to optimize breast cancer therapy in the future
Recruiting
- Conditions
- Breast cancer
- Registration Number
- NL-OMON28678
- Lead Sponsor
- Erasmus MC
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 20
Inclusion Criteria
•Age ≥18 years
•WHO performance status 0 or 1
Exclusion Criteria
•Planned treatment with TAC (taxanes concomitant with anthracyclines) courses
•Current therapeutical use of anti-coagulant (coumarin derivates, warfarin, heparin or low molecular weight heparin [LMWH]) whereby a short interruption of drug use is not allowed. LMWH use in a prophylactic dose is allowed.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary end point is the concordance between the ex vivo anthracycline sensitivity test and the in vivo response to anthracycline-based NAC on MRI.
- Secondary Outcome Measures
Name Time Method Explore whether the use of different cut-off values for the ex vivo anthracycline sensitivity assay could even better predict the in vivo anthracycline response.